Low-Dose Ketamine in Children With ADNP Syndrome

  • STATUS
    Recruiting
  • participants needed
    10
  • sponsor
    Alexander Kolevzon
Send
Updated on 16 February 2024
See if I qualify
ketamine

Summary

This is a Phase 2A, single dose, open-label study to evaluate the safety, tolerability, and efficacy of a low-dose, 40-minute infusion into the veins (intravenous infusion or "IV") of ketamine in children with ADNP syndrome (Activity-Dependent Neuroprotective Protein). The study team will enroll 10 participants, ages 5 to 12, at Mount Sinai. The study participation is expected to last 4 weeks and will include 5 scheduled clinic visits in order to complete safety monitoring, clinical assessments, and biomarker collection. At the conclusion of this study, the study team expects to demonstrate the safety and tolerability of low-dose ketamine in children with ADNP syndrome. Additionally, the study team anticipates identifying meaningful signals of efficacy in clinical outcome measures using RNA and DNA sequencing to analyze ADNP protein expression and DNA methylation profiles, a natural process by which methyl groups are added to the DNA to change its activity, in order to assess sensitivity to change with low-dose ketamine treatment and inform future phase 3 studies. Ketamine is not currently approved by the Food and Drug Administration to treat this syndrome, but it is approved for use in children in other situations, for example in anesthesia.

Details
Condition ADNP Syndrome
Age 5years - 12years
Treatment Ketamine
Clinical Study IdentifierNCT04388774
SponsorAlexander Kolevzon
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

to 12 years old (inclusive) at the time of informed consent
Has a diagnosis of ADNP syndrome, confirmed by genetic testing prior to subject randomization
Has a Clinical Global Impression-Severity score of 4 (moderately ill) or greater at screening
Any concomitant medication, including anti-epileptic and/or behavioral medications, supplements, and special diets, must be at a stable dose for at least 4 weeks before
Has an English-speaking caregiver capable of providing informed consent and able to attend all scheduled study visits, oversee the administration of study drug, and provide feedback regarding the subject's behavior and other symptoms as described in the protocol
Provide assent to the protocol (when applicable)
Has a caregiver who will agree not to post any of the subject's personal medical data related to the study or information related to the study on any website or social media site (e.g., Facebook and Twitter) until they have been notified that the study is completed
Age-specific blood pressure parameters for inclusion in the study will be based on established guidelines

Exclusion Criteria

Has a concomitant disease (e.g., gastrointestinal, renal, hepatic, endocrine, respiratory, or cardiovascular system disease) or condition or any clinically significant finding at screening that could interfere with the conduct of the study or that would pose an unacceptable risk to the subject in this study
Has clinically significant lab abnormalities or vital signs at the time of screening (e.g., alanine aminotransferase or aspartate aminotransferase >2.5 upper limit of normal; total bilirubin or creatinine >1.5 upper limit of normal). Re-testing of safety labs is allowed
Hypertension that is not well controlled (systolic BP >130-140 mm Hg or diastolic BP >85-95 mm Hg depending on age)
A blood pressure reading over 160/90 or two separate readings over 140/90 at screening or baseline visits
Thyroid impairment, as reflected by a TSH > 4.2 mU/L
Cardiac disease, as reflected by an EKG that is abnormal and of concern for cardiac disease
Has had changes in his/her medication regimen within the previous month
Has a history of uncontrollable seizure disorder or seizure episodes within 1 month of screening
Has a history of suicidal behavior or considered by the investigator to be at high risk of suicide
Has a current or past history of psychotic symptoms
Has enrolled in any clinical trial or used of any investigational agent, device, and/or investigational procedure within the 30 days before screening or does so concurrently with this study
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

ketamine

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.